Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

Tandem Diabetes Care announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap ...

The BNY Mellon Small/Mid Cap Growth Fund (Class A at NAV) returned 3.05% during the third quarter of 2024. Read more here.

BNY Mellon Research Growth Fund (Class A at NAV) underperformed its benchmark, the Russell 1000® Growth Index, during the ...

OK, I've been a little late coming up with my holiday gift guide, as we've already passed both Black Friday and Cyber Monday.

Martin Makary, a Johns Hopkins surgeon and researcher, has been critical of the FDA. He could have the most influence over device policy among Trump’s nominees. CEO Dev Kurdikar said the decision may ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $90.00. The ...